Loading...
•
Dec 31, 2021
Novavax Q4 2021 Earnings Report
Novavax reported financial results for Q4 and full year 2021.
Key Takeaways
Novavax's Q4 2021 revenue was $222 million, and the net loss was $846 million. The company had $1.5 billion in cash, cash equivalents, marketable securities, and restricted cash as of December 31, 2021. Novavax expects to achieve full year 2022 total revenue of between $4 billion and $5 billion.
Achieved Multiple Regulatory Authorizations Globally for COVID-19 Vaccine
Completed Multiple Regulatory Submissions Globally for COVID-19 Vaccine
Advanced Purchase Agreement
Novavax revenue for the fourth quarter and full year ended 2021 were $222 million and $1.1 billion, respectively
Forward Guidance
Novavax expects to achieve full year 2022 total revenue of between $4 billion and $5 billion.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...